Switch theme
Sign up to access all valuation multiples
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
2013
71
LTM Revenue $12.3M
Last FY EBITDA -$65.9M
$58.9M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Verrica Pharmaceuticals has a last 12-month revenue (LTM) of $12.3M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Verrica Pharmaceuticals achieved revenue of $7.6M and an EBITDA of -$65.9M.
Verrica Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Verrica Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $12.3M | XXX | $7.6M | XXX | XXX | XXX |
| Gross Profit | $9.9M | XXX | $4.8M | XXX | XXX | XXX |
| Gross Margin | 80% | XXX | 64% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$65.9M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -871% | XXX | XXX | XXX |
| EBIT | -$47.0M | XXX | -$65.8M | XXX | XXX | XXX |
| EBIT Margin | -383% | XXX | -870% | XXX | XXX | XXX |
| Net Profit | -$59.3M | XXX | -$76.6M | XXX | XXX | XXX |
| Net Margin | -483% | XXX | -1012% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Verrica Pharmaceuticals's stock price is $0.
Verrica Pharmaceuticals has current market cap of $46.1M, and EV of $58.9M.
See Verrica Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $58.9M | $46.1M | XXX | XXX | XXX | XXX | $-1.00 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Verrica Pharmaceuticals has market cap of $46.1M and EV of $58.9M.
Verrica Pharmaceuticals's trades at 7.8x EV/Revenue multiple, and -0.9x EV/EBITDA.
Equity research analysts estimate Verrica Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Verrica Pharmaceuticals has a P/E ratio of -0.8x.
See valuation multiples for Verrica Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $46.1M | XXX | $46.1M | XXX | XXX | XXX |
| EV (current) | $58.9M | XXX | $58.9M | XXX | XXX | XXX |
| EV/Revenue | 4.8x | XXX | 7.8x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -0.9x | XXX | XXX | XXX |
| EV/EBIT | -1.3x | XXX | -0.9x | XXX | XXX | XXX |
| EV/Gross Profit | 6.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.8x | XXX | -0.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -1.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialVerrica Pharmaceuticals's last 12 month revenue growth is 105%
Verrica Pharmaceuticals's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $1.0M for the same period.
Verrica Pharmaceuticals's rule of 40 is -1109% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Verrica Pharmaceuticals's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Verrica Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 105% | XXX | 112% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -871% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -1109% | XXX | -766% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 156% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 934% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Verrica Pharmaceuticals acquired XXX companies to date.
Last acquisition by Verrica Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Verrica Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Verrica Pharmaceuticals founded? | Verrica Pharmaceuticals was founded in 2013. |
| Where is Verrica Pharmaceuticals headquartered? | Verrica Pharmaceuticals is headquartered in United States of America. |
| How many employees does Verrica Pharmaceuticals have? | As of today, Verrica Pharmaceuticals has 71 employees. |
| Who is the CEO of Verrica Pharmaceuticals? | Verrica Pharmaceuticals's CEO is Dr. Jayson Rieger. |
| Is Verrica Pharmaceuticals publicy listed? | Yes, Verrica Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Verrica Pharmaceuticals? | Verrica Pharmaceuticals trades under VRCA ticker. |
| When did Verrica Pharmaceuticals go public? | Verrica Pharmaceuticals went public in 2018. |
| Who are competitors of Verrica Pharmaceuticals? | Similar companies to Verrica Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Verrica Pharmaceuticals? | Verrica Pharmaceuticals's current market cap is $46.1M |
| What is the current revenue of Verrica Pharmaceuticals? | Verrica Pharmaceuticals's last 12 months revenue is $12.3M. |
| What is the current revenue growth of Verrica Pharmaceuticals? | Verrica Pharmaceuticals revenue growth (NTM/LTM) is 105%. |
| What is the current EV/Revenue multiple of Verrica Pharmaceuticals? | Current revenue multiple of Verrica Pharmaceuticals is 4.8x. |
| Is Verrica Pharmaceuticals profitable? | Yes, Verrica Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
